Avadel Pharmaceuticals plc (NASDAQ ... Enrollment is ongoing in our Phase 3 REVITALYZ study, where we are evaluating LUMRYZ's ...

Such forward-looking statements are based on the current beliefs of Recursion's and Exscientia's respective management as well as assumptions ... the ability to realize the benefits of the proposed ...

TileDB, the database designed for scientific discovery, announced today it is now utilized by 50% of the top 20 global pharmaceutical companies, including industry giant Boehringer Ingelheim. This ...

A third of American adults consider sleep one of their top three health priorities, and while most of them prioritize ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

The new department would work with the White House and Office of Management and Budget to "drive large-scale ... Musk, ranked ...

Rising growth expectations are likely to boost corporate earnings, which may also benefit from lower statutory and effective ... The chief beneficiaries include mid-caps, fossil fuel energy companies, ...

GT Independence, a financial management services (FMS ... announced today it is now utilized by 50% of the top 20 global ...

Thank you for standing by, and welcome to the Rocket Companies third quarter 2024 earnings conference call. (Operator Instructions). I'd now like to turn the call over to Sharon Ng, Head of Investor ...

Foley & Larder LLP recently sponsored TEDAI 2024 in San Francisco, drawing industry leaders and change makers to share meaningful new ideas in ...

A few of these participants also employ various organic and inorganic growth strategies. Recently, for example, Glenmark Life Science, a pharmaceutical giant in India, announced an investment of US$ ...